Eli Lilly and Company $LLY Shares Bought by AlTi Global Inc.

Key Points

• AlTi Global increased its Eli Lilly position by 27% in the second quarter, bringing its holdings to 5,208 shares worth approximately $6.25 million. Institutional investors and hedge funds collectively own 82.53% of LLY.
• Eli Lilly delivered strong quarterly results, reporting adjusted earnings of $8.38 per share versus the $6.40 consensus estimate and revenue of $22.97 billion, up 47.7% year over year. The company reaffirmed fiscal 2026 earnings guidance of $35.50–$36.50 per share.
• Shares remain richly valued but analyst sentiment is positive. LLY traded near its 52-week high with a P/E ratio of 42.97, while analysts maintained a “Moderate Buy” consensus and a $1,292.18 average price target; recent insider sales were conducted under pre-arranged trading plans.

AlTi Global Inc. lifted its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 27.0% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 5,208 shares of the company's stock after buying an additional 1,108 shares during the quarter. AlTi Global Inc.'s holdings in Eli Lilly and Company were worth $6,247,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in LLY. NorthStar Asset Management LLC NJ lifted its holdings in shares of Eli Lilly and Company by 5.8% in the second quarter. NorthStar Asset Management LLC NJ now owns 2,587 shares of the company's stock valued at $3,103,000 after purchasing an additional 141 shares in the last quarter. BLB&B Advisors LLC lifted its stake in Eli Lilly and Company by 479.3% in the 2nd quarter. BLB&B Advisors LLC now owns 10,670 shares of the company's stock valued at $12,798,000 after buying an additional 8,828 shares in the last quarter. Convergence Financial LLC grew its holdings in Eli Lilly and Company by 95.1% during the 2nd quarter. Convergence Financial LLC now owns 8,507 shares of the company's stock valued at $10,204,000 after buying an additional 4,147 shares during the last quarter. TBH Global Asset Management LLC grew its holdings in Eli Lilly and Company by 24.5% during the 2nd quarter. TBH Global Asset Management LLC now owns 3,133 shares of the company's stock valued at $3,757,000 after buying an additional 616 shares during the last quarter. Finally, SFE Investment Counsel increased its position in Eli Lilly and Company by 2.5% during the second quarter. SFE Investment Counsel now owns 5,971 shares of the company's stock worth $7,162,000 after buying an additional 144 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,280.62 on Thursday. Eli Lilly and Company has a 52 week low of $685.15 and a 52 week high of $1,292.65. The stock has a fifty day moving average price of $1,176.04 and a 200 day moving average price of $1,056.96. The firm has a market capitalization of $1.21 trillion, a P/E ratio of 42.97, a PEG ratio of 1.45 and a beta of 0.51. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the company posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company's dividend payout ratio is 23.22%.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares of the company's stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the sale, the executive vice president owned 54,147 shares of the company's stock, valued at approximately $63,628,139.70. This trade represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. Corporate insiders own 0.14% of the company's stock.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity-drug momentum remains the primary catalyst. Lilly’s Zepbound sales reportedly rose 46%, while its broader GLP-1 portfolio outperformed Novo Nordisk’s in the latest quarter. Investors are also focused on Lilly’s potential oral obesity treatments and retatrutide, which could expand the company’s addressable market beyond weekly injections. How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
• Positive Sentiment: Fundamentals support the bullish narrative. Lilly’s latest quarter exceeded consensus estimates, with earnings per share of $8.38 versus $6.40 expected and revenue of $22.97 billion versus $20.82 billion expected. Revenue increased 47.7% year over year, and fiscal 2026 earnings guidance remains strong. Could Eli Lilly Be Worth More Than SpaceX by the End of 2026?
• Positive Sentiment: Pipeline and business-development activity is broadening. Lilly is advancing oral and metabolic-health candidates, completing early-stage work on lepodisiran and LY4086940, and studying a new LY4065967 formulation. Partnerships with OmniAb and AlzeCure add potential neuroscience and central-nervous-system opportunities. Eli Lilly Expands Neuroscience Reach With New Drug Deals
• Neutral Sentiment: Market conditions provided additional support. Lower Treasury yields and gains across major biotech and pharmaceutical stocks improved the sector backdrop, although these factors are not specific to Lilly. Dow Jones Futures: S&P 500, Nasdaq Rise on Treasury Move
• Negative Sentiment: Valuation and competition are key risks. With a market capitalization above $1 trillion and a premium earnings multiple, Lilly must continue delivering strong growth. Novo Nordisk and potential entrants such as Pfizer remain competitors in oral and injectable obesity treatments.
• Negative Sentiment: An insider sale creates a limited headwind. EVP Patrik Jonsson sold 6,500 shares for approximately $7.6 million under a pre-arranged Rule 10b5-1 plan. Because the sale was scheduled in advance, it is a weaker bearish signal. SEC Insider Transaction Filing

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Guggenheim upped their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a "buy" rating in a research report on Monday, July 13th. JPMorgan Chase & Co. lifted their price objective on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 7th. Sanford C. Bernstein boosted their target price on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an "outperform" rating in a research note on Tuesday, July 14th. Weiss Ratings lowered shares of Eli Lilly and Company from a "buy (b)" rating to a "buy (b-)" rating in a report on Tuesday, August 11th. Finally, Bank of America lifted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a report on Friday, July 10th. One analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $1,292.18.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source